April 2025 in “Journal of Cosmetic Dermatology” Azathioprine is a safe and effective long-term treatment for severe alopecia areata, significantly improving hair regrowth.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
May 2026 in “Dermatology and Therapy” Ritlecitinib improves hair growth and quality of life in severe alopecia areata with longer use.
2 citations
,
March 2024 in “Dermatologic Surgery” The chemical peel improved the appearance of hand spots safely and effectively.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
19 citations
,
January 2022 in “Journal of Nanomaterials” NH-Tween-80 is a promising stable gel for treating acne.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
4 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is safe for treating alopecia areata for up to 48 weeks.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
5 citations
,
January 1995 in “Journal of Dermatological Treatment” Calcipotriol does not improve the effectiveness of squaric acid dibutylester in treating alopecia areata.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
Triamcinolone acetonide and betamethasone 1.75 mg/ml are both effective for treating alopecia areata.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
27 citations
,
June 2017 in “Expert opinion on investigational drugs” New anti-acne medications are being tested to offer alternatives to current treatments.
April 2022 in “Journal of evolution of medical and dental sciences” Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.
May 2024 in “Journal of the Egyptian Womenʼs Dermatologic Society” Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.